lymphoma

Conference Coverage

Watch and Wait vs Initial Treatment for Advanced FL

12/03/2020

Journal of Clinical Pathways

Research Reports

Real-World Analysis of Outpatient Rasburicase to Prevent and Manage Tumor Lysis Syndrome in Newly Diagnosed Adults With Leukemia or Lymphoma

03/16/2020

Alex R. Cockerham , PharmD, RPh, MSc;

William Irish , PhD;

Edward Drea , PharmD;

Michael P. Ryan , MS;

Lucio Gordan , MD;

Yvonne Barnes , DNP, RN;

Scott C. Howard , MD, MSc;

Abstract: Rasburicase, a recombinant urate oxidase used to manage hyperuricemia in patients at risk of tumor lysis syndrome, is increasingly being used in outpatient settings, but outcomes with this approach have not...

...

03/16/2020

Journal of Clinical Pathways

Research in Review

Blood Condition Increases Risk of Adverse Events After ASCT for Patients With Lymphoma

02/13/2017

JCP Editors

Patients with an age-related blood condition undergoing autologous stem cell transplantation (ASCT) for lymphoma are at greater risk of adverse outcomes, reports a new study published in the Journal of Clinical...

...

02/13/2017

Journal of Clinical Pathways

Research in Review

Blood Condition Increases Risk of Adverse Events After ASCT in Lymphoma

01/13/2017

JCP Editors

Patients with an age-related blood condition undergoing autologous stem-cell transplantation (ASCT) for lymphoma are at greater risk of adverse outcomes, says a new study published in the Journal of Clinical...

...

01/13/2017

Journal of Clinical Pathways

Research in Review

Routine Imaging for DLBCL Post-Remission Does Not Improve Survival

12/14/2015

JCP Editors

Routine imaging for diffuse large B-cell lymphoma (DLBCL) in patients after first complete remission does not translate into better survival, suggests a study in the online Journal of Clinical Oncology. Considering...

...

12/14/2015

Journal of Clinical Pathways

Research in Review

Early Trials Show Promising Results for Lymphoma Immunotherapy Drug

12/10/2015

JCP Editors

SD-101, a novel immunotherapy drug for low-grade lymphoma, reported promising results from a phase 1/2 clinical trial on Saturday at the American Society of Hematology (ASH) Annual Meeting in Orlando, Florida...

...

12/10/2015

Journal of Clinical Pathways